Italia markets open in 2 hours 23 minutes

CAPR Sep 2024 7.500 put

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
2,55000,0000 (0,00%)
In data: 02:18PM EDT. Mercato aperto.
Schermo intero
Chiusura precedente2,5500
Aperto2,5500
Denaro0,0000
Domanda3,2000
Prezzo d'esercizio7,50
Scadenza2024-09-20
Min-Max giorno2,5500 - 2,5500
Contratto - Min-MaxN/D
Volume1
Open Interest5
  • GlobeNewswire

    Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society

    -24-Month Open Label Extension Data from HOPE-2 Study Supports CAP-1002’s Sustained Efficacy and Safety in Treating Duchenne Muscular Dystrophy- -Company’s StealthX™ Technology Shows Promise of Exosome-Based Delivery of ASOs- SAN DIEGO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announce

  • GlobeNewswire

    Capricor Therapeutics Announces $23 Million Registered Direct Offering

    SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, today announced that it has entered into definitive agreements with its commercial partner, Nippon Shinyaku, Co., Ltd. and funds associated with Highbridge Capital Management, LLC. for the issuance and sale of 4,935,621 shares of its commo

  • GlobeNewswire

    Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy

    -FDA Feedback on the Proposed Key Clinical and Regulatory Requirements Confirms CAP-1002’s Path Towards a Biologics License Application (BLA)- -Company On Track to Complete HOPE-3 Enrollment and Report Outcome from Interim Analysis in Q4 2023- -Conference Call and Webcast Today at 8:30 a.m. ET- SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatme